FDA Approves Abrilada, Biosimilar to Humira, for JIA and Other Inflammatory Disorders
News
The U. S. Food and Drug Administration (FDA) has approved Abrilada (adalimumab-afzb), a biosimilar to Humira, for the treatment of juvenile idiopathic arthritis (JIA) in patients 4 and older and for ... Read more